Navigation Links
CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Date:2/21/2008

evation Acute Coronary Syndrome; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Efficacy and Safety of Ranolazine in Chronic Angina: Observations from the Randomized, Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST

Regadenoson

Heart Rate Response to Adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST

Additional information regarding the ACC 57th Annual Scientific Sessions can be accessed at http://acc08.acc.org/Pages/default.aspx.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed for potential treatment of cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking sta
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Md., May 5, 2011 GenVec, Inc. (NASDAQ: GNVCD) today ... letter from The NASDAQ Stock Market ("NASDAQ") advising that it ... GenVec had received a notice of deficiency on ... compliance with NASDAQ Marketplace Rules because the bid price of ...
... Reportlinker.com announces that a new market research report ... Tumor Markers - Global Pipeline Analysis, Competitive Landscape ... http://www.reportlinker.com/p0490349/Tumor-Markers---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html Tumor Markers - ... to 2017 Summary ...
... 4, 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... material, today announced that its chairman and CEO, Guy Cook, ... Equity Conference at the Hard Rock Hotel in Hollywood, Florida, ... At the time of the presentation, a live audio ...
Cached Biology Technology:GenVec Regains Compliance with NASDAQ Listing Requirements 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:7/10/2014)... are a big, bad sea scorpion. , One minute, ... any prey in sight. The next, thanks to a ... to trolling for weaker, soft-bodied animals you stumble upon ... giant pterygotid eurypterid, the largest arthropod that ever lived. ... journal Biology Letters , dramatically re-interprets the creature,s ...
(Date:7/10/2014)... The controversy centres around a family of enzymes known ... heme group in their active site. At the centre ... which becomes oxidised (ferryl) when a reacting heme is ... that has remained unanswered for decades is whether this ... hydroxyl group (OH). Resolving this fundamental question has implications ...
(Date:7/10/2014)... research from The University of Texas Health Science Center ... Real (IYG), a health education program designed to delay ... reduce dating violence behaviors among minority youth. , According ... percent of high school youth are victims of physical ... 20 percent are victims of emotional dating violence. Previous ...
Breaking Biology News(10 mins):Extinct sea scorpion gets a Yale eye exam, with surprising results 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... Brian Chen has been awarded a prestigious Sloan Research ... Formation, investigates a big subject: deciphering the assembly instructions ... neural circuits wire up with precision. One of the ... the correct synaptic contacts during its development when faced ...
... named Brontomerus mcintoshi , or "thunder-thighs" after its enormously powerful ... is described in a paper recently published in the journal ... the U.K. and the U.S. A member of the ... Brachiosaurus , Brontomerus may have used its powerful ...
... the crowd? Is that all I,ll ever be? ... Do you ... the Crowd" It may seem paradoxical, but being ... UCLA life scientists. Biologists Kimberly Pollard and Daniel ... alarm-call vocalizations in eight species of rodents that live in social ...
Cached Biology News:Prestigious Sloan Fellowship awarded 2New 'thunder-thighs' dinosaur discovered 2New 'thunder-thighs' dinosaur discovered 3Even in a crowd, you remain unique, UCLA life scientists report 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Analyst Software has been optimized for the ... allow the software to quickly and accurately ... well of an ELISA plate or each ... Software has been customized to incorporate standard ...
... An easy-to-use solution that enables fully automated ... 400 Hybridization Station has been designed to ... the throughput necessary to perform a wide ... performed in the range 485C; denaturations of ...
The Piezo Power MicroDissection (PPMD) system is designed for rapid isolation of single cells or small cell areas...
Biology Products: